



Mailing Address:  
ADAP Advocacy  
PO Box 846  
Nags Head, NC 27959

Office Address:  
1630 Connecticut Ave, NW  
Suite 500  
Washington, DC 20009

CEO:  
Brandon M. Macsata  
Washington, D.C.

Board of Directors:

*Co-Chair*  
Guy Anthony  
Brooklyn, NY

*Co-Chair*  
Wanda Brendle, Moss, R.N.  
Winston-Salem, NC

*Secretary*  
Lisa Johnson-Lett  
Birmingham, AL

*Treasurer*  
Robert "Bobby" L. Dorsey, Esq.  
La Plata, MD

Erin Darling, Esq.  
Washington, DC

Lyne Fortin, B.Pharm, MBA  
Montreal, Canada

Maria Mejia  
Tamarac, FL

Shabbir Imber Saifdar  
San Francisco, CA

Jennifer Vaughan  
Watsonville, CA

Marcus A. Wilson  
Orlando, FL

Directors Emeritus:  
Michelle Anderson  
William Arnold – *in memoriam*  
John D. Kemp, Esq.  
Gary Rose – *in memoriam*  
Joyce Turner Keller  
Rani Whitfield, M.D.

[adapadvocacy.org](http://adapadvocacy.org)

## ADAP Advocacy Urges Congress to Reject 340B Special Carveouts

### *Improving Patient Access and Affordability Depends on the Universal Implementation of the 340B Drug Pricing Program Rebate Model*

For Immediate Release:  
February 6, 2026

Media Contact:  
[info@adapadvocacy.org](mailto:info@adapadvocacy.org)

WASHINGTON, D.C. – ADAP Advocacy cautions against “special” carveouts for Federally Qualified Health Centers (FQHCs), or any other covered entities, participating in the federal 340B Drug Pricing Program. The Trump Administration has joined a growing chorus calling for long-overdue reforms to the 340B Program, most notably by proposing a rebate model to replace the current upfront payments that drug manufacturers make to covered entities, which have led to increasing waste, fraud, and abuse.

A 340B Rebate Model would put patients *before* providers, allowing them—for the first time—to see whether they receive the benefit of lower 340B prices when they pay out of pocket at the pharmacy counter. Legislation introduced in the U.S. Congress by Representatives Jack Bergman and Jake Auchincloss would undermine this reform effort. It is provider-focused, not patient-centric.

Brandon M. Macsata, CEO of ADAP Advocacy, stated: “**The idea that the 340B Rebate Model would prevent FQHCs from dispensing necessary medicines to patients is unfounded and perpetuated by large systems that benefit from the lack of data reporting and transparency in the program. A rebate model helps ensure the integrity of the 340B program, ultimately benefiting vulnerable safety-net providers and patients. This model isn’t an experiment because State AIDS Drug Assistance Programs have largely operated under a similar model for decades. Over the last twenty years, ADAPs have been serving nearly twice as many patients, and the percentage of 340B rebate dollars as a share of the overall budget has increased from seven percent to fifty-one percent.**”

The Bergman-Auchincloss bill, though well-intended, is a step in the wrong direction as it decreases the likelihood of improving patient access and affordability.

To learn more about ADAP Advocacy or the 340B Program, please email [info@adapadvocacy.org](mailto:info@adapadvocacy.org).

#####

***About ADAP Advocacy:*** The ADAP Advocacy mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community members, health care providers, government officials, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient education programs, and foster greater community collaboration.